Although researchers first identified the fat-soluble vitamin cholecalciferol almost a century ago and studies have now largely elucidated the transcriptional mechanism of action of its hormonal form, 1␣, 25(OH) 
INTRODUCTION
Research has shown that the mechanism of action of vitamin D 3 , through its hormonal form, 1␣,25-dihydroxyvitamin D 3 [1␣,25(OH) 2 D 3 ], involves a nuclear receptor [vitamin D receptor (VDR)] that regulates the transcription of several target genes in a variety of vitamin D target cells that are primarily involved in calcium homeostasis and cell differentiation (1) . To allow vitamin D to achieve these important regulatory functions, normal physiology has evolved several specific proteins that constitute the vitamin D signal transduction system (Figure 1) .
These specialized proteins, in addition to the VDR and its associated transcriptional coactivators, include the plasma transport protein, vitamin D binding protein (DBP); the activating cytochrome P450s (CYP2R1, CYP27A1, and CYP27B1); and the catabolic cytochrome P450 CYP24A1. CYP24A1 plays a critical role in the degradation of both 25-hydroxyvitamin D 3 [25(OH)D 3 ] and 1␣,25(OH) 2 D 3 through a side-chain hydroxylation and cleavage pathway known as C-24 oxidation (5). Recent research using the CYP24A1-null mouse has shown that CYP24A1 plays a vital role in vivo in that its absence leads to an inability to degrade vitamin D metabolites to C-24 oxidation products or 26,23-lactone products. This resulted in hypercalcemia, nephrocalcinosis, and death in 50% of animals (6) .
Because vitamin D toxicity resulting from excessive vitamin D intakes (hypervitaminosis D) is also accompanied by hypercalcemia, toxicity is remarkably similar to the CYP24A1-null mouse. One can therefore postulate that overactivity of the vitamin D signal transduction system in hypervitaminosis D is also the result of an inability of the catabolic system involving CYP24A1 to keep up with the target cell levels of activated vitamin D metabolites. Indeed, investigators have postulated several variations of this theme, each involving a different metabolite (or metabolites) that, together, overwhelm the vitamin D signal transduction process, to explain the vitamin D toxicity of hypervitaminosis D. I review these explanations of vitamin D toxicity, along with the animal and human data assembled to support them.
IMPORTANT DETERMINANTS OF VITAMIN D PHARMACOKINETICS RELEVANT TO HYPERVITAMINOSIS D
Vitamin D 3 is a lipophilic molecule similar to its closely related lipid precursor cholesterol, so it requires a protein carrier for solubility in plasma. Its mono-, di-, and tri-hydroxylated metabolites show progressively increasing polarity, culminating in the water-soluble biliary form calcitroic acid (7) . When absorbed from the gut, vitamin D enters the circulation on chylomicrons first, and it is only slowly transferred to DBP (8) . Vitamin D has relatively low affinity for DBP; reviews estimate this at between 1 ҂ 10 Ҁ5 and 1 ҂ 10 Ҁ7 mol/L (9, 10). Transport of dietary vitamin D contrasts significantly with that of vitamin D 3 made during skin synthesis, which is mainly bound to DBP (8) . The consequence of chylomicron transport of dietary vitamin D is the possibility of uptake by peripheral tissues, such as adipose tissue and muscle, due to the action of lipoprotein lipase (11) . The liver takes up the vitamin D left in the chylomicron remnant and quickly removes it from the bloodstream.
The loss into tissue and liver pools thus logically explains the short plasma half-life, Ȃ4 -6 h, of physiologically relevant doses of vitamin D (11) . Similar studies with radiolabeled vitamin D have shown that the whole-body half-life is Ȃ2 mo (11) .
The liver converts vitamin D into 25(OH)D, a process that some attribute to a microsomal cytochrome P450 enzyme, CYP2R1, or the mitochondrial cytochrome P450 CYP27A1; neither is subject to tight regulation (12 (1, 12) under in vitro conditions. Of course, although research has proven that renal CYP27B1 synthesizes the circulating pool of 1␣,25(OH) 2 D 3 , the amount of vitamin D channeled into this active form is tightly regulated (17) and studies have estimated that it is only a small percentage of the total body pool of vitamin D.
Measurements of the plasma level show that circulating 1␣,25(OH) 2 D 3 is in the picomolar range, a concentration 1000 times lower than that of 25(OH)D. Molecular probes for CYP27B1 mRNA based on reverse transcriptase-polymerase chain reaction and for CYP27B1 protein based on immune localization studies have shown that this "activating" CYP is expressed not only in the kidney but also in several extrarenal tissues; in addition, it is subject to different regulation than the renal enzyme (Figure 1; 2, 3 ). This extrarenal 1␣-hydroxylase appears to have a paracrine or autocrine function to augment local production of 1␣,25(OH) 2 The study design did not allow for repeated measurements of plasma vitamin D metabolite levels as the hypercalcemia developed in the animals, leaving open the possibility that plasma 1␣,25(OH) 2 D 3 initially rose and was subsequently suppressed in response to hypercalcemia. Nevertheless, other animal studies of hypervitaminosis D (19, 20) have also repeatedly failed to demonstrate a significant elevation of the hormonal form.
The 10-fold increments in the dose of vitamin D 3 used in the study by Shephard 3 . Based on a variety of studies in several animal species, it appears that the plasma 25(OH)D concentrations associated with toxicity are always in excess of 375 nmol/L. Furthermore, small differences between various mammalian species used in animal experiments are largely irrelevant to the toxicity issue and render the animal data valuable to our discussion. 2) Vitamin D intake raises plasma 25(OH)D to mol/L concentrations that exceed the DBP binding capacity and "free 25(OH)D" enters the cell, where it has direct effects on gene expression.
ANECDOTAL EVIDENCE FROM STUDIES OF VITAMIN D INTOXICATION IN HUMANS
3) Vitamin D intake raises the concentrations of many vitamin D metabolites, especially vitamin D itself and 25(OH)D. These concentrations exceed the DBP binding capacity and cause release of "free" 1␣,25(OH) 2 D, which enters target cells.
In weighing each of these hypotheses, it is useful to consider other factors, in addition to elevated dietary vitamin D intakes, that result in symptoms of vitamin D toxicity. One disease that can result in vitamin D toxicity is the granulomatous condition sarcoidosis, but only when strong evidence exists that the mechanism involves consistently elevated plasma 1␣,25(OH) 2 D 3 concentrations due to overexpression of unregulated extrarenal CYP27B1 in the face of normal concentrations of 25(OH)D (37) (38) (39) . In addition, the widespread use of calcitriol or its analogues to treat secondary hyperparathyroidism in chronic kidney disease occasionally results in such symptoms as hypercalcemia, hyperphosphatemia, and soft-tissue calcifications; these symptoms are almost certainly the result of overexposure of target cells to active analogue (40) .
Thus, toxicity due to 1␣,25(OH) 2 D (hypothesis 1 above) is well known but correlated with a high plasma concentration of the hormone. But when we observe toxicity due to high vitamin D intakes, it is rarely accompanied by elevated total 1␣,25(OH) 2 D 3 concentrations. Thus, although overproduction of the active form due to excessive precursor levels (hypothesis 1) might be the most obvious explanation of hypervitaminosis D, animal and human data do not strongly support it.
Before any discussion of alternate hypotheses 2 or 3, we must return to the model for the normal action of 1␣,25(OH) 2 D 3 . The low affinity of 1␣,25(OH) 2 D 3 for the transport protein DBP and its high affinity for VDR dominate normal physiology, making it the only ligand with access to the transcriptional signal transduction machinery. However, in vitamin D intoxication, overloading by various vitamin D metabolites significantly compromises the capacity of the DBP by allowing other metabolites to enter the cell nucleus. Of all the inactive metabolites, 25(OH)D 3 has the strongest affinity for the VDR and thus, at sufficiently high concentrations, could stimulate transcription. Some evidence using highly artificial in vitro transactivation systems indicates that D metabolites other than 1␣,25(OH) 2 D 3 might directly stimulate gene transcription (41) . Whether Ȃ750 nmol/L of plasma 25(OH)D 3 , a level associated with hypercalcemia in many human and animal studies (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) , is sufficiently high enough to overcome plasma DBP binding and enter the cell's nucleus to stimulate gene transcription is debatable.
Considerable discussion in the literature focuses on the exact concentration of 1␣,25(OH) 2 D 3 required for gene expression. The original theory for classical steroid action postulated that most circulating hormone is protein bound in the plasma and gains entry to cells in a "free" form of the hormone that crosses the cell membrane, binds to the nuclear receptor, and triggers gene expression. Many researchers have assumed that 1␣,25(OH) 2 D 3 , being a secosteroid, mimics other steroids and thus its "free" form is the most important (Figure 1) (42) .
In fact, Bikle et al (43, 44) In the investigation of the family accidentally intoxicated by vitamin D 3 in peanut oil discussed above (36) , the authors used the methods of Bikle (43, 44) to investigate free 1␣,25(OH) 2 D 3 concentrations. They found that unlike total 1␣,25(OH) 2 D 3 concentrations, which remained within the normal range in 8 of 11 family members, free 1␣,25(OH) 2 D 3 concentrations were 2 SDs above the reference range in 6 of 9 patients studied. The authors concluded that the micromolar concentrations of 25(OH)D and other metabolites displace free 1␣,25(OH) 2 D from DBP.
These investigators also simulated in vitro the displacement of 1␣,25(OH) 2 D from DBP noted in hypervitaminotic plasma by adding 25(OH)D 3 to normal serum at the 800-nmol/L concentration found in hypervitaminotic plasma. They found a virtual doubling of free 1␣,25(OH) 2 D concentrations. Although these results are quite convincing, few other data are available to support hypothesis 3, and one must conclude that the theory remains unproven.
CONCLUSIONS
Our current understanding of the components of the vitamin D signal transduction machinery (DBP, activating CYPs, VDR, and CYP24) allows us to theorize in broad terms about how vitamin D toxicity might arise from hypervitaminosis D. Of the 3 hypotheses put forward to explain the triggering event for toxicity, increases in total 25(OH)D and free 1␣,25(OH) 2 D concentrations are the most plausible, although they remain unproven. However, even in the absence of definitive evidence to establish the responsible metabolite, the wealth of animal studies and human anecdotal reports of vitamin D intoxication indicate that plasma 25(OH)D 3 is a good biomarker for toxicity, and the threshold for toxic symptoms is Ȃ750 nmol/L. This threshold value implies that 25(OH)D concentrations up to the currently considered upper limit of the normal range, namely 250 nmol/L, are safe and still leave a broad margin for error because values significantly higher than this value have never been associated with toxicity.
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